Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 11/20 | 0.39 |
| ▸ | CDK2 | P24941 | 11/20 | 0.39 |
| ▸ | PNP | P00491 | 4/20 | 0.39 |
| ▸ | MGMT | P16455 | 6/20 | 0.38 |
| ▸ | CDK1 | P06493 | 10/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 10/20 | 0.37 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10383666 | 0.76 | CDK1 (0.47) | CCNA2CDK2PNPMGMTCDK1 | |
| SCHEMBL5484380 | 0.71 | PNP (0.44) | CCNA2CDK2PNPCDK1CCNB1 | |
| SCHEMBL3300895 | 0.70 | PIN1 (0.67) | CCNA2CDK2PNPMGMTCDK1 | |
| SCHEMBL2242819 | 0.68 | PNP (0.44) | PNPHPRT1 | |
| SCHEMBL2242808 | 0.67 | HPRT1 (0.34) | CCNA2CDK2PNPCDK1CCNB1 | |
| SCHEMBL31676894 | 0.65 | FBP1 (0.33) | — | |
| SCHEMBL6356987 | 0.64 | PNP (0.54) | PNP | |
| SCHEMBL8933964 | 0.64 | HPRT1 (0.35) | HPRT1 | |
| SCHEMBL3396382 | 0.64 | PNP (0.52) | PNP | |
| SCHEMBL3878333 | 0.63 | FBP1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517858-B1 | Prodrugs of pharmaceuticals with improved bioavailability | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-14 | — | — | US | claimed |
| US-6599887-B2 | Aids, herpes virus | CHIMERIX, INC. | 2003-07-29 | — | — | US | disclosed |
| US-6448392-B1 | LIPID, ESPECIALLY PHOSPHOLIPID, DERIVATIVES OF MODIFIED ANTIVIRAL NUCLEOSIDE ANALOGUES CAN BE INTEGRATED INTO STRUCTURE OF LIPOSOMES, FORMING STABLE LIPOSOMAL COMPLEX, DELIVER GREATER AMOUNTS OF DRUGS TO CELLS WITH LESS TOXICITY | CHIMERIX, INC. | 2002-09-10 | — | — | US | disclosed |
| US-20010033862-A1 | Methods of treating viral infections using antiviral liponucleotides | HOSTETLER KARL Y (US) | 2001-10-25 | — | — | US | disclosed |
| EP-0350287-B1 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | CHIMERIX INC (US) | 2000-09-27 | — | — | EP | disclosed |
| US-5223263-A | Viricide complex; aids therapy | VICAL, INC. (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0350287-A2 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | NeXstar Pharmaceuticals, Inc. (US) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010033862-A1 | Methods of treating viral infections using antiviral liponucleotides | PHOSPHO1, TK1, TYMP | CCNA2 3938/4885CDK2 3427/4885PNP 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.